The relationship between the Tirzepatida and sleep apnea it gained considerable attention after clinical trials showed a significant reduction of the interruptions in breathing throughout the night, and in people with obesity.
The obstructive sleep apnea is a condition in which the airways become partially or completely blocked, over and over again while the person is sleeping. As a result, your breathing may stop for a few seconds, several times per hour.
In addition to ensuring that the quality of your sleep, this is a condition that is associated with sleepiness during the day, changes in the cardiovascular and other health problems.
Obesity is one of the main factors related to the development and exacerbation of the disease.
It is precisely in this respect that it has led the researchers to assess whether the significant weight loss that is caused by the Tirzepatida it could also help to improve breathing during sleep.
The study SURMOUNT-OSA have brought significant results.
After 52 weeks, the people who are treated with Tirzepatida showed a significant reduction in the number of events that are holding your breath, and hipopneia per hour, in addition to weight loss, the lower the load to the lack of oxygen during sleep, and improvement in various measures of health.
These data are promising, but it doesn't mean that anyone who snore may have to use Tirzepatida or someone who uses the DARK you can leave the machine on its own.
In this article, you are going to understand what the studies really showed it, and how to interpret the information.
- Important: this content is purely informative and does not replace evaluation by a doctor. The diagnosis and treatment of sleep-disordered breathing should be carried out by a health-care professional.
What is obstructive sleep apnea?
The obstructive sleep apnea occurs when the muscles and structures of the throat relaxes during sleep, and to reduce or temporarily block the passage of air.
When there is a complete blockage, a breath-hold.
When the air only decreases significantly, there is a hipopneia.
The body senses the reduction of oxygen and causes a small, waking up, so that the breathing is re-established.
These awakenings can occur dozens or even hundreds of times during the night.
The person often does not even realize that you woke up.
Even so, sleep is fragmented.
What are the most common symptoms?
One of the symptoms of the most well-known is the loud snoring, and frequent.
However, snoring is not automatically mean you have the illness.
Other possible signs include the following:
- breathing pauses and perceived by the partner;
- the feeling of suffocation during sleep
- a dry mouth upon awakening;
- a headache in the morning;
- sleep, a little night;
- trouble concentrating;
- irritability;
- drowsiness during the day.
Some of the people after years of believing that you're just tired, when, in fact, have a breathing disorder in sleep.
By which obesity increases the risk?
The excess of adipose tissue may build up is also at the edge of the structures of the upper respiratory tract.
This can reduce the amount of space available for the passage of air.
Obesity can also change the mechanical function of the rib cage, and breathe.
For this reason, there is a link between being overweight and sleep apnea.
This does not mean that only people with obesity will develop the condition.
Anatomical features of the lower jaw and the size of the tongue, the tonsils, the age, sex, gender, and genetic factors also have an influence.
But in people with obesity to lose weight, you can produce an improvement.
How to Tirzepatida could you help me?
The Tirzepatida does not work, then opening it directly in the throat during the night.
Your main aim in this context is not related to the treatment of obesity.
The drug acts on the receptors and GIP, and GLP-1 may help to reduce appetite, increase satiety, and lower food intake.
Over time, this will result in a significant reduction of the weight.
When the amount of fat tissue slows down, it can occur in less pressure, and less accumulation of fat around the airways.
It is precisely this mechanism that helps to explain the relationship between the Tirzepatida and sleep apnea.
The SURMOUNT-LOVING?
The SURMOUNT-OSA, was a program to phase 3 is designed specifically for the study of Tirzepatida in adults with obesity and obstructive sleep apnea is moderate to severe.
There were two studies in parallel for up to 52 weeks.
Study 1 included participants who did not use the therapy with positive airway pressure, also known as PAP.
Study 2 also included people who have used PEP.
In total, there is approximately 469 subjects were randomized.
They were Tirzepatida at the maximum tolerated dose of 10 mg, or 15 mg) or placebo.
We also were given the intervention is related to a way of life.
As the researchers measure the improvement?
The key indicator used was the the index of the long-hipopneiacalled in THERE, or AHI.
This number shows how many times, on average, breathing, or decrease significantly over the course of an hour of sleep.
In a simple way:
the higher the number, the greater is the severity of the condition.
The diagnosis and classification is, however, dependent on the interpretation of a complete examination of the rest.
For this reason, one should not be considered in isolation.
How much of the index is down?
The participants began the study with pictures of important.
In study 1, the average rate was about 51,5 events per hour.
After the 52 weeks in the group treated with Tirzepatida showed an average reduction of approximately 25,3 events per hour.
On placebo, the reduction was approximately The 5.3 events per hour.
In study 2, the index of the initial medium was approximately 49,5 events per hour.
In the reduction with a Tirzepatida was about By 29.3 events per hourwhile the lead was down to about 5.5 in the event, for time.
These results represent a significant difference between the two groups.
They also show that the treatment has not worked for the weight, there's been a change in the objective lens in the breath that recorded during the night.
This means that the disease has disappeared?"
Not all of the people.
The response rate varied among the participants.
Some had improved enough for you to reach much lower levels of respiratory events.
The others continued to the changes, although it is less intense.
For this reason, it is not appropriate to turn to the middle of the study, in the promise of the individual.
Even after significant weight loss, some people may still need to treat in a particular way.
Weight loss explains why the improvement?
A large part is probably related to the decrease of the weight.
A further analysis of the studies that SURMOUNT-OSA have found a relationship between the amount of weight lost, and increase in the index of respiratory events.
Participants who lost the most weight to the generally showed greater reductions in the severity of the condition.
The researchers are continuing to investigate whether there are also effects that do not depend solely on weight loss.
To date, however, the weight loss seems to be a key component of the improvement was observed.
What is extremely hypoxic?
Not all of the interruptions in breathing have exactly the same effect.
During a breath-hold, or hipopneia, the amount of oxygen in your blood may fall.
Loading hypoxic seek to assess how much of the time, and that the intensity of these episodes for the reduction of oxygen to take place during the night.
In the study SURMOUNT-LOVING the Tirzepatida also significantly reduced the load on hypoxic-related episodes of disordered breathing.
This result is important because of the impact of the disease depends not only on the number of stoppages.
The amount of the lack of oxygen, may also have relevance to cardiovascular disease.
Improved sleep?
Yes.
In addition to the examinations, the goals, the researchers assessed how the participants perceived their sleep and daily functioning.
We observed that improvements in the measures relating to:
- impairment caused by sleep;
- sleep disorders;
- during the day,
- quality-of-life.
The analysis, published later, they found improvement in several indicators that are reported by the participants.
This shows that the change did not happen only on the results of the survey.
The patient had also noticed the improvement in the functional.
Sleepiness during the day, you can do better?
You can.
When someone passes by in the night, showing small, waking up to the breath, to sleep, can no longer meet properly, its restoring function.
With appropriate treatment, some people have reported:
- less drowsiness;
- the largest available;
- the best concentration, and
- the smaller feel tired when you wake up.
But excessive sleepiness has a number of causes.
You could still tired of the same, with the improvement of respiratory events, if there is a deprivation of sleep, anemia, depression, underactive thyroid, certain drugs and other conditions.
Tirzepatida reduce your snoring?
Other countries may diminish over time as that occurs, the improvement of the obstruction of the airways, and reduced weight.
Analysis, up-to-date SURMOUNT-OSA is also assessed symptoms, such as snoring, fatigue, and sleep quality.
However, snoring, and sleep apnea they are not exactly the same thing.
A person can snore, and without presenting respiratory events is sufficient to fill in the diagnostic criteria.
It is also possible to introduce the disease to a snoring extremely loud.
I wonder if I have long, only for the noise?
No.
The diagnosis involves a clinical examination and an examination of the rest.
Polysomnography is considered to be one of the main forms of assessment.
In some situations, testing, home sleep, it can also be used.
They report parameters, such as the breath, the flow of air, oxygen, and the frequency of the event.
The result enables us to estimate the extent of the problem.
What is CPAP therapy?
CPAP means continuous positive airway pressure in the airways.
The device then sends the air through a mask while you sleep.
This pressure helps to keep the airway open and prevents them to collapse over and over again.
It is one of the most effective treatments to boards, moderate, and severe.
The effectiveness, however, depends on the intended use.
Some people are difficult to adapt to fit in to the pressure.
Can't stop the GENERATOR after I lose weight?
Not on their own.
This is one of the most important points in this article.
Weight loss can significantly reduce the severity of the problem, but that does not mean that the disorder is completely gone.
A person may feel a lot better, and also to submit the event and breathing during the night.
If there has been a large reduction of weight, your doctor may recommend a re-evaluation or a re-examination of the rest.
Only after that review is not possible to know whether the GENERATOR can be adjusted or discontinued.
And if I am unable to use CPAP?
There are other strategies that are used, depending on the cause and severity.
It can also be considered as options, such as:
- devices, oral;
- change the position to go to sleep,
- the treatment of obesity.
- assessment of the respiratory system;
- for certain surgical procedures.
The choice depends on the anatomy and clinical presentation.
The Tirzepatida should not be seen merely as an alternative to those who “don't like it in the DARK”.
It is a very important factor in individuals with obesity, but it does not replace other therapies.
Tirzepatida that is approved specifically for that long?
The situation depends on the country.
In the United States, the FDA has approved it in December 2024, the Zepbound, which contains Tirzepatida for the treatment of obstructive sleep apnea of moderate-to-severe adult obesity in combination with diet, with a reduction of calorie restriction and increased physical activity.
It was the first approved drug to specific by the FDA for this situation.
In Brazil, the page will display on the Fda to Mounjaro viewed today has obstructive sleep apnea, as one of the co-morbid conditions that are related to your weight, you can either be part of the criteria for the indication for the control of chronic weight.
This is a different take on that with the indication of the regulatory former is identical with the specific indication is approved in the United States of america.
Why is this difference in regulatory matters.
Medicines may receive a different indications in different countries.
The existence of a scientific study, the positive does not mean that any of the regulatory agencies have adopted exactly the same as the display.
Because of this, articles on health, they need to distinguish between:
what the study found
to
for which the medicine is officially approved in the country.
This is particularly important in the content of YMYL.
What was the decision by the FDA?
In December 2024, the FDA has approved Tirzepatida in adults with obesity and obstructive sleep apnea is moderate to severe.
The decision was based primarily on the results of two studies SURMOUNT-LOVING.
The agency pointed out that the treatment significantly reduced the index of respiratory events compared with placebo.
The FDA has also indicated that the improvement is likely related to a reduction in the weight of the body.
Those who took part in the study?
This point is very important.
The results do not come from the people who just roncavam.
The participants were:
- obesity.
- the diagnosis is established;
- the framework, moderate, or severe
- follow-up within a clinical trial.
For this reason, we are not able to extrapolate to the same results for every person.
The study used doses, the maximum allowed is 10 or 15 mg.
This does not mean that a person should have to increase their dosage in order to improve more rapidly with the breath.
Lose weight without Tirzepatida it can also help you with?
Yes.
The reduction in the weight recommended for people with obesity and sleep-disordered breathing prior to the existence of the Tirzepatida.
Diet, physical activity, bariatric surgery, and other ways you can improve your table when producing a significant reduction in excess weight.
The Tirzepatida provides a new tool in the treatment of obesity.
It doesn't change the fact that bad habits, adequate sleep, and follow-up continue to be important to you.
Sleeping on your side can help you with?
For some people, the respiratory events occur more often when they sleep face-up.
This is called a long position.
In such cases, you sleep on your side, you can reduce a part of the show.
But this approach doesn't work in the same way for all people, and it should not substitute for a go-to treatment for the disease is moderate or severe, without trial.
Alcohol can make the problem worse?
You can.
Alcohol can relax you even more of the muscles in the airways and worsen the episodes of obstruction of some people.
You can also change the architecture of normal sleep patterns.
For this reason, people with breathing disorders, nocturnal, can receive guidance in order to reduce or avoid the use near the time of going to sleep.
Blood pressure has also been improved?
Yes.
The study SURMOUNT-OSA and found improvement in systolic blood pressure among the participants of the treaties.
This is important because obesity, high blood pressure, and respiratory disorders, nocturnal often appear together.
The reduction in weight and improvement of sleep can contribute to a cardiometabólico better.
However, this does not mean that the high blood pressure medications need to be stopped.
And the kidneys.
The study also evaluated C-reactive protein high sensitivity, also known as hsCRP.
This is a marker that is related to the systemic inflammation and the risk of cardiometabólico.
The treatment produced improvement of this marker in comparison with placebo.
Again, this is part of a series of changes seen in the weight loss and improvement in respiratory arrest.
It does not mean that Tirzepatida is a medication which is specifically intended to “address the inflammation”.
Improve your skin-reduces the risk of heart disease?
We know that the disease is associated with a higher risk of heart disease.
We also know that SURMOUNT-OSA have found improvements in different markers are considered to be favourable.
It is important that it does not exceed what the study found.
The study was designed primarily to assess the respiratory events during sleep, and is not to prove that the reduction of heart problems, STROKE, or death from cardiovascular.
Therefore, the results of which are cardiometabolicamente beneficial, but it should not be turned into a promise for the prevention of cardiovascular disease.
The side effects were for you.
The most frequent adverse events continued to be mostly of the gastro-intestinal.
Some of these include nausea, diarrhea, vomiting, and constipation.
Most of them were considered to be mild or moderate in essays.
This profile is similar to that observed in other studies of Tirzepatida.
In the presence of the condition and the breathing doesn't eliminate all of the same precautions, and contraindications that are used for the treatment of.
How long did it take you to do better?
The study followed participants for up to 52 weeks.
The improvement has occurred over time.
This makes sense, because the weight loss is also what happens over the course of months.
We are not to expect that one application may cut off all the episodes of breathing in the night and during the day.
The treatment needs to be evaluated within a long-term strategy.
Do I need to repeat polysomnography after I lose weight?
It can also be noted.
Especially if there is a significant reduction in the weight and / or major changes in their symptoms.
A re-examination may show:
- if the index has fallen;
- if the gravity has changed and
- if the pressure in the GENERATOR needs to be set;
- if there is still a need for specific therapy.
The timing should be decided on by the professional in charge.
When searching for a review?
Some of the signs, and justify the research, especially when it comes to on together:
- snoring is heavy;
- breathing pauses seen in sleep;
- waking up choking;
- unrefreshing sleep;
- excessive sleepiness during the day;
- trouble concentrating;
- blood pressure is difficult to control.
A person does not need to wait until you develop serious symptoms to seek an evaluation.
Appropriate diagnosis and treatment can greatly improve your quality of sleep and overall health.
Frequently asked questions
Tirzepatida improve your sleep apnea?
In people with obesity, and disease, moderate-to-severe studied at the SURMOUNT-OSA, there was a significant reduction in respiratory events after 52 weeks.
The index fell?
In the study, with no PAR, the average reduction was approximately 25.3 events per hour, with a Tirzepatida, versus a 5.3 with a placebo.
In a study involving the users of the PAP, and the reductions were approximately 29.3 cross-5.5 events per hour, respectively.
Can I stop using CPAP after I lose weight?
Not without re-examination. It may be necessary to carry out a new examination of sleep before you have to change or stop treatment.
Tirzepatida a cure for the disease?
It is not appropriate to use the word cure. Some people may experience a great improvement in, or even meet the criteria of resolution, while the other continued to record the event.
Those who snore, can use Tirzepatida?
Snoring by itself is not an indication. It is necessary to consider whether there is a respiratory illness, and separately assess whether the person meets the criteria for treatment with Tirzepatida.
The FDA has approved Tirzepatida so long?
Yes. In the United States, Zepbound was approved in December of 2024 and obstructive sleep apnea of moderate-to-severe adult obesity.
And in the united states?
In an indication of the brazilian Mounjaro for the control of chronic and body weight, the Fda cites the development of obstructive sleep apnea as a possible co-morbid conditions related to being overweight. The indication that regulations need to be followed according to the instructions of the brazilian force and effect.
Conclusion
The study SURMOUNT-OPTIMIZATION have led to a new perspective on the relationship between obesity and sleep apnea.
In adults, obesity, and disease, moderate-to-severe, Tirzepatida has significantly reduced the number of respiratory events during sleep.
In the first study, the index has fallen an average of 25.3 events per hour, with a Tirzepatida, versus a 5.3 with a placebo.
In the second case, the average reductions were 29.3 5.5 events per hour, respectively.
Also, we observed that improvements in weight, load, hypoxic, blood pressure, inflammatory markers and measures of the quality of your sleep.
These results led to the FDA-approved Tirzepatida in the United States of certain persons with obesity, and disease, moderate-to-serious condition.
In Brazil, the obstructive sleep apnea occurs between the co-morbid conditions related to the weight on the display of the Mounjaro for the control of chronic weight.
In spite of the impressive results, CPAP and other treatments should not be stopped just because there was a weight loss or improvement in symptoms.
The right way to figure out if the condition has really improved is to undertake a re-assessment when indicated.
The main message is that obesity can bring about benefits that go far beyond the scale and, in some people, a significant contribution to improving the quality of your breathing while you are sleeping.
References
The U. S. Food and Drug Administration (FDA). FDA Approves First Medication for Obstructive Sleep Apnea. Zepbound (tirzepatide).
The brazilian National agency of Sanitary Surveillance (Anvisa). Mounjaro® (tirzepatida): a new indication for the control of chronic weight.
Tirzepatide for sleep-disordered breathing in and SURMOUNT-LOVING: the Time course and association with body weight. 2025.
The Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-LOVING participants with obstructive sleep apnea and obesity. 2025.
Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in the SURMOUNT-LOVING. 2026.
Content is up-to-date in September, 2026.
Read On To Find Out
Nausea, with tirzepatida: is it normal?
Tirzepatida the cause of indigestion? To understand the onset of discomfort after eating
Tirzepatida gives you diarrhea? Find out why it happens and what to do
